I Wish I Could Take His Pain”: A Mother Watches Her Child Endure Chemo and Immunotherapy 3637c

Chemo day four did not arrive loudly.
It did not announce itself with alarms or sudden chaos.
It came quietly, settling into Cylus’s body the way a storm settles into the air before anyone realizes how violent it will become.

Immunotherapy day three followed closely behind, layering itself over everything he was already enduring, turning discomfort into pain and pain into something far harder to describe.

Cylus is hurting.
Not in one place.

Not in one clear way that can be easily treated.
But everywhere.
The kind of pain that moves through nerves, that lights up the body from the inside, that makes even rest feel like work.

The immunotherapy — dinutuximab — is doing what it is designed to do, and that knowledge is both reassuring and devastating at the same time.

Dinutuximab targets GD2 antigens, which sit on the surface of neuroblastoma cells.

It binds to them, flags them, and tells the immune system to attack.
But neuroblastoma is a cancer of immature nerve cells in the sympathetic nervous system, and that means the treatment cannot cleanly separate what is dangerous from what is healthy.

So while it damages cancer cells, it also damages healthy nerve cells.
That is where the pain comes from.
Deep, sharp, burning nerve pain that spreads across the entire body.

To manage that pain, doctors have placed Cylus on a PCA pump, carefully balancing medications to give him relief without overwhelming his small system.
Even with that support, the pain still breaks through.

High fevers come and go.
Immune reactions flare suddenly.
His body is constantly reacting, adjusting, fighting, and recalibrating.
It is exhausting for him in ways that go far beyond physical tiredness.

It drains him emotionally, too, even if he cannot fully articulate why.

Friday morning brought an X-ray of his pelvis.
Everyone knew its limitations.
An X-ray is not as detailed as a CT scan.

It does not offer the clarity of an MIBG scan.
But still, the results mattered.
And when they came back, they brought a moment of cautious relief.

For the first time in many months, doctors could not see any new tumors.

There was no obvious progression.
The area appeared stable.
In the world of pediatric cancer, “stable” is not a small word.
It does not mean cured.
It does not mean safe.

But it means the disease is not advancing — and sometimes, that pause is everything.

For Cylus’s mother, that news landed with mixed emotions.
Relief, yes.
But also heartbreak.
Because stability has come at such a high cost.

Nothing in her life has ever broken her heart the way watching her child endure this has.
Not once.
But over and over again.

Just one week ago, life looked different.

They were celebrating his birthday.
He was walking on his own.
Eating without struggle.
Smiling easily.
Playing like a child should.
Those moments may have looked ordinary to others, but to her they were sacred — proof that joy still existed between treatments, proof that her son was still fully himself.

And then, just as quickly, everything changed again.
Hospital rooms replaced birthday decorations.
IV lines replaced toys.
Pain replaced laughter.
Cylus does not understand why this keeps happening to him.

He does not understand words like immunotherapy, antibodies, or cancer cells.
He only knows that his body hurts in ways it did not before, and that the things he could do last week suddenly feel impossible.

This is not his first experience with dinutuximab.
Back in August, during his initial rounds, the pain was overwhelming.
This time, doctors say he is reacting better, and that matters.

But “better” does not mean easy.
It does not mean gentle.
It simply means survivable — a word that feels too heavy to ever attach to a child.

As a mother, she wishes she could take his place.
She wishes she could carry the pain instead — the nerve damage, the fevers, the exhaustion.
She would do it without hesitation if it were possible.
But she cannot.
All she can do is stay beside him, advocate for him, comfort him, and love him through every moment of this journey.

And through it all, Cylus continues to push forward.
Even when he hurts.
Even when he is tired.
Even when his body feels like it is fighting itself.
He does not think of himself as brave.
He simply keeps going, because that is what he has learned to do.

There is hope beyond the hospital walls.
News recently came from CHOP — the Children’s Hospital of Philadelphia.
Initial approval issues have been resolved.
Barriers that once seemed immovable are beginning to shift.
They are now one step closer to potential clinical trials, one step closer to additional options in the fight against this aggressive disease.

Neuroblastoma is the most common solid tumor cancer in children under the age of five.
It is also one of the deadliest pediatric cancers.
It does not just attack the body — it reshapes entire families, entire futures, entire ways of living.
Parents become advocates overnight.
Ordinary life becomes a sequence of scans, labs, medications, and waiting.

They had hoped to go home Tuesday.
Home now represents comfort, familiarity, and a brief escape from constant alarms and clinical routines.
But blood transfusions became necessary, pushing that plan back nearly half a day.
Another reminder that cancer dictates the schedule, not hope.

Still, Cylus moves forward.
And his family moves with him.
Every step is taken together.
Every decision is weighed carefully.
Every ounce of strength is borrowed from love and determination.

This journey is not defined only by pain.
It is defined by resilience.
By moments of stability.
By a child who continues to fight even when the cost is more than anyone should ever have to pay.
And always, at his side, is a mother who refuses to let him face this road alone — no matter how long it is, and no matter how hard it becomes.